851 related items for PubMed ID: 19776644
1. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S, Sar F, Bengi-Bozkurt O, Kazancioglu R.
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[Abstract] [Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Robles NR, Romero B, Fernandez-Carbonero E, Sánchez-Casado E, Cubero JJ.
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
[Abstract] [Full Text] [Related]
3. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J.
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[Abstract] [Full Text] [Related]
4. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB.
J Nephrol; 2007 May; 20(4):410-6. PubMed ID: 17879206
[Abstract] [Full Text] [Related]
5. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW, Won YW, Yi JH, Kim HJ.
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[Abstract] [Full Text] [Related]
6. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[Abstract] [Full Text] [Related]
7. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
Hillebrand U, Suwelack BM, Loley K, Lang D, Reuter S, Amler S, Pavenstädt H, Hausberg M, Büssemaker E.
Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
[Abstract] [Full Text] [Related]
8. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R.
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[Abstract] [Full Text] [Related]
9. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Montanaro D, Gropuzzo M, Tulissi P, Vallone C, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani GL, Sainz M, Bresadola F, Mioni G.
Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
[Abstract] [Full Text] [Related]
10. Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
Inoue A, Babazono T, Iwamoto Y.
Am J Hypertens; 2008 Mar; 21(3):317-22. PubMed ID: 18202667
[Abstract] [Full Text] [Related]
11. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[Abstract] [Full Text] [Related]
12. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U, Chaisuvannarat V.
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[Abstract] [Full Text] [Related]
13. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T, Pohl M, Misselwitz J, John U.
Kidney Blood Press Res; 2009 May; 32(6):440-4. PubMed ID: 20016211
[Abstract] [Full Text] [Related]
14. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
Fang W, Oreopoulos DG, Bargman JM.
Nephrol Dial Transplant; 2008 Nov; 23(11):3704-10. PubMed ID: 18567695
[Abstract] [Full Text] [Related]
15. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease.
Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS.
J Hypertens Suppl; 2006 Mar; 24(1):S95-9. PubMed ID: 16601581
[Abstract] [Full Text] [Related]
16. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[Abstract] [Full Text] [Related]
17. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[Abstract] [Full Text] [Related]
18. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
Suzuki H, Kanno Y, Nakamoto H, Okada H, Sugahara S.
Clin Exp Hypertens; 2005 Mar; 27(2-3):129-38. PubMed ID: 15835375
[Abstract] [Full Text] [Related]
19. The effects of spironolactone on nephron function in patients with diabetic nephropathy.
Ustundag A, Tugrul A, Ustundag S, Sut N, Demirkan B.
Ren Fail; 2008 Mar; 30(10):982-91. PubMed ID: 19016150
[Abstract] [Full Text] [Related]
20. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
Cotter J, Oliveira P, Cunha P, Polónia J.
Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
